论文部分内容阅读
由中国工程院院士、天津中医学院第一附属医院院长石学敏教授经过30余年的临床实践,研制的“丹芪偏瘫胶囊”是治疗脑血管疾病的有效制剂。日前,经国家药品监督管理局批准,获得国家新药证书,成为天津市第一家医院开发研制生产的具有自主知识产权和高科技含量的国家三类新药。该药经605例二、三期临床研究显示,治疗中风有很好的疗效,证实可迅速修复受损脑细胞,溶解脑血栓,改善脑缺血状态,恢复肢体功能,降低血液粘稠度,且疗效可靠。该药品已由天津石天药业集团投入大批量生产,近期可投放
Academician Shi Xuemin, a member of the Chinese Academy of Engineering and dean of the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, has developed the “Danzhi Hemiplegia Capsule” as an effective preparation for the treatment of cerebrovascular diseases after more than 30 years of clinical practice. Recently, with the approval of the State Drug Administration, it has obtained the National New Drug Certificate, and has become the country’s three new drugs with independent intellectual property rights and high-tech content developed and produced by Tianjin’s first hospital. The drug has been used in Phase II and III clinical studies of 605 patients to show that the treatment of stroke has a good effect, and it can be confirmed that it can quickly repair damaged brain cells, dissolve cerebral thrombosis, improve cerebral ischemia, restore limb function, and reduce blood viscosity. And the effect is reliable. The drug has been put into mass production by Tianjin Shitian Pharmaceutical Group and can be put into operation in the near future.